search
Back to results

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Primary Purpose

Obesity, Overweight

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
LY3437943
Placebo
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Nutritional or Metabolism Disorder, Weight Loss, Overnutrition, Incretins, Hormones, Physiological Effects of Drugs

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants must have a Body Mass Index (BMI) ) ≥30 and ≤50 kilograms per square meter (kg/m²), or ≥27 kg/m² and <30 kg/m², with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease
  • Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires

Exclusion Criteria:

  • Participants must not have type 1 or type 2 diabetes mellitus
  • Participants must not have had an increase or decrease in body weight > more than 5 kg (11 pounds) within the past 3 months
  • Participants must not have had surgery for obesity or plan to have such surgery during the study
  • Participants must not be using medications that promote weight loss or cause weight gain
  • Participants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men)
  • Participants must not have used marijuana within the last 3 months.
  • Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months
  • Participants must not have active cancer within the last 5 years
  • Participants must not have uncontrolled high blood pressure
  • Participants must not have liver disease other than non-alcoholic fatty liver disease
  • Participants must not have renal impairment with estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2
  • Participants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented human immunodeficiency virus infection
  • Participants must not have a major problem with depression or other mental illness within the last 2 years
  • Participants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)
  • Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of childbearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)

Sites / Locations

  • Perseverance Research Center
  • Anaheim Clinical Trials, LLC
  • Valley Research
  • Velocity Clinical Research, Huntington Park
  • Velocity Clinical Research, Huntington Park
  • Southern California Dermatology, Inc.
  • Coastal Metabolic Research Centre
  • Diablo Clinical Research, Inc.
  • East Coast Institute for Research, LLC
  • Suncoast Clinical Research, Inc.
  • Encore Medical Research - Weston
  • Springfield Diabetes & Endocrine Center
  • Cotton O'Neil Diabetes and Endocrinology Center
  • Tandem Clinical Research,LLC
  • StudyMetrix Research
  • Amici Clinical Research LLC
  • Intend Research, LLC
  • Allegheny Endocrinology Associates
  • New Phase Research and Development
  • Texas Diabetes & Endocrinology, P.A.
  • Dallas Diabetes Research Center
  • Juno Research
  • Endocrine Ips, Pllc
  • Southern Endocrinology Associates
  • Rainier Clinical Research Center
  • Private Practice - Dr. Paola Mansilla-Letelier
  • GCM Medical Group, PSC - Hato Rey Site
  • San Juan City Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Placebo

1 milligram (mg) LY3437943

4 mg LY3437943 (2 mg)

4 mg LY3437943

8 mg LY3437943 (2 mg)

8 mg LY3437943 (4 mg)

12 mg LY3437943 (2 mg)

Arm Description

Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).

Participants received 1 mg LY3437943 administered as SC injection QW.

Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.

Participants received 4 mg LY3437943 administered as SC injection QW.

Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.

Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.

Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.

Outcomes

Primary Outcome Measures

Mean Percent Change From Baseline in Body Weight
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.

Secondary Outcome Measures

Mean Percent Change From Baseline in Body Weight
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction
Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kilograms per square meter (kg/m2), ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction
Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction
Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction
Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction
Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction
Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Mean Change From Baseline in Body Weight
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Mean Change From Baseline in Body Weight
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Mean Change From Baseline in BMI
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Mean Change From Baseline in BMI
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Mean Change From Baseline in Waist Circumference
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Mean Change From Baseline in Waist Circumference
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.

Full Information

First Posted
May 10, 2021
Last Updated
August 23, 2023
Sponsor
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT04881760
Brief Title
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Official Title
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
May 20, 2021 (Actual)
Primary Completion Date
May 16, 2022 (Actual)
Study Completion Date
November 22, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Overweight
Keywords
Nutritional or Metabolism Disorder, Weight Loss, Overnutrition, Incretins, Hormones, Physiological Effects of Drugs

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
338 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).
Arm Title
1 milligram (mg) LY3437943
Arm Type
Experimental
Arm Description
Participants received 1 mg LY3437943 administered as SC injection QW.
Arm Title
4 mg LY3437943 (2 mg)
Arm Type
Experimental
Arm Description
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
Arm Title
4 mg LY3437943
Arm Type
Experimental
Arm Description
Participants received 4 mg LY3437943 administered as SC injection QW.
Arm Title
8 mg LY3437943 (2 mg)
Arm Type
Experimental
Arm Description
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
Arm Title
8 mg LY3437943 (4 mg)
Arm Type
Experimental
Arm Description
Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
Arm Title
12 mg LY3437943 (2 mg)
Arm Type
Experimental
Arm Description
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.
Intervention Type
Drug
Intervention Name(s)
LY3437943
Intervention Description
Administered SC
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered SC
Primary Outcome Measure Information:
Title
Mean Percent Change From Baseline in Body Weight
Description
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Time Frame
Baseline, Week 24
Secondary Outcome Measure Information:
Title
Mean Percent Change From Baseline in Body Weight
Description
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Time Frame
Baseline, Week 48
Title
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction
Description
Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kilograms per square meter (kg/m2), ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Time Frame
Week 24
Title
Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction
Description
Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Time Frame
Week 48
Title
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction
Description
Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Time Frame
Week 24
Title
Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction
Description
Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Time Frame
Week 48
Title
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction
Description
Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Time Frame
Week 24
Title
Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction
Description
Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum [<36 kg/m2, ≥36 kg/m2] and sex [female, male] as fixed effects, and baseline body weight as a covariate.
Time Frame
Week 48
Title
Mean Change From Baseline in Body Weight
Description
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Time Frame
Baseline, Week 24
Title
Mean Change From Baseline in Body Weight
Description
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Time Frame
Baseline, Week 48
Title
Mean Change From Baseline in BMI
Description
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Time Frame
Baseline, Week 24
Title
Mean Change From Baseline in BMI
Description
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Time Frame
Baseline, Week 48
Title
Mean Change From Baseline in Waist Circumference
Description
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Time Frame
Baseline, Week 24
Title
Mean Change From Baseline in Waist Circumference
Description
LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment*Time + Baseline BMI (< 36kg/m2 vs. >=36 kg/m2)*Time + Sex (Female vs. Male)*Time + Baseline*Time.
Time Frame
Baseline, Week 48

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants must have a Body Mass Index (BMI) ) ≥30 and ≤50 kilograms per square meter (kg/m²), or ≥27 kg/m² and <30 kg/m², with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires Exclusion Criteria: Participants must not have type 1 or type 2 diabetes mellitus Participants must not have had an increase or decrease in body weight > more than 5 kg (11 pounds) within the past 3 months Participants must not have had surgery for obesity or plan to have such surgery during the study Participants must not be using medications that promote weight loss or cause weight gain Participants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men) Participants must not have used marijuana within the last 3 months. Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months Participants must not have active cancer within the last 5 years Participants must not have uncontrolled high blood pressure Participants must not have liver disease other than non-alcoholic fatty liver disease Participants must not have renal impairment with estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2 Participants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented human immunodeficiency virus infection Participants must not have a major problem with depression or other mental illness within the last 2 years Participants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative) Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of childbearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Perseverance Research Center
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85254
Country
United States
Facility Name
Anaheim Clinical Trials, LLC
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Valley Research
City
Fresno
State/Province
California
ZIP/Postal Code
93720
Country
United States
Facility Name
Velocity Clinical Research, Huntington Park
City
Huntington Park
State/Province
California
ZIP/Postal Code
90255
Country
United States
Facility Name
Velocity Clinical Research, Huntington Park
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Southern California Dermatology, Inc.
City
Santa Ana
State/Province
California
ZIP/Postal Code
92701
Country
United States
Facility Name
Coastal Metabolic Research Centre
City
Ventura
State/Province
California
ZIP/Postal Code
93003
Country
United States
Facility Name
Diablo Clinical Research, Inc.
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
East Coast Institute for Research, LLC
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
Suncoast Clinical Research, Inc.
City
New Port Richey
State/Province
Florida
ZIP/Postal Code
34652
Country
United States
Facility Name
Encore Medical Research - Weston
City
Weston
State/Province
Florida
ZIP/Postal Code
33331
Country
United States
Facility Name
Springfield Diabetes & Endocrine Center
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62711
Country
United States
Facility Name
Cotton O'Neil Diabetes and Endocrinology Center
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
Facility Name
Tandem Clinical Research,LLC
City
Marrero
State/Province
Louisiana
ZIP/Postal Code
70072
Country
United States
Facility Name
StudyMetrix Research
City
Saint Peters
State/Province
Missouri
ZIP/Postal Code
63303
Country
United States
Facility Name
Amici Clinical Research LLC
City
Raritan
State/Province
New Jersey
ZIP/Postal Code
08869
Country
United States
Facility Name
Intend Research, LLC
City
Norman
State/Province
Oklahoma
ZIP/Postal Code
73069
Country
United States
Facility Name
Allegheny Endocrinology Associates
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
Facility Name
New Phase Research and Development
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37909
Country
United States
Facility Name
Texas Diabetes & Endocrinology, P.A.
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Facility Name
Dallas Diabetes Research Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Juno Research
City
Houston
State/Province
Texas
ZIP/Postal Code
77054
Country
United States
Facility Name
Endocrine Ips, Pllc
City
Houston
State/Province
Texas
ZIP/Postal Code
77079
Country
United States
Facility Name
Southern Endocrinology Associates
City
Mesquite
State/Province
Texas
ZIP/Postal Code
75149
Country
United States
Facility Name
Rainier Clinical Research Center
City
Renton
State/Province
Washington
ZIP/Postal Code
98057
Country
United States
Facility Name
Private Practice - Dr. Paola Mansilla-Letelier
City
Guaynabo
ZIP/Postal Code
00970
Country
Puerto Rico
Facility Name
GCM Medical Group, PSC - Hato Rey Site
City
San Juan
ZIP/Postal Code
00917
Country
Puerto Rico
Facility Name
San Juan City Hospital
City
San Juan
ZIP/Postal Code
00935
Country
Puerto Rico

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD Sharing Time Frame
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD Sharing Access Criteria
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD Sharing URL
https://vivli.org/
Links:
URL
https://trials.lillytrialguide.com/en-US/trial/36s0UdwlFjVCXwfbif2fkc
Description
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Learn more about this trial

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

We'll reach out to this number within 24 hrs